Cannabis and CBD Stocks are Old News, The Next Hot Peripheral Sector is Here!

New York, NY -- April 16, 2020 -- InvestorsHub NewsWire -- via Traders News Source -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies’ issues their latest research “The Next Hot Sector”

In February, BioElectronics Corporation (OTC: BIEL) obtained a new 510(k) clearance from the U.S. Food and Drug Administration (FDA). This new, over-the-counter marketing clearance was granted for the drug-free ActiPatch® medical device, for adjunctive treatment of musculoskeletal pain. The ActiPatch was already FDA-cleared for over-the-counter treatment of pain from knee osteoarthritis and plantar fasciitis (heel pain) in 2017.

Arrayit Corporation (OTC: ARYC) works in the biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products. Last August, the company was approved by a leading Medicare Administrative Contractor (MAC) on behalf of the Centers for Medicare and Medicaid Services (CMS) as a new allergy testing services healthcare provider for Medicare Part B.

Ever wish you were aware of a hot new sector before it experiences explosive growth? Hot new sector in its infancy gaining traction now READ MORE
Copy and paste to browser may be required https://www.industrynews.tips/

Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) recently issued a shareholder update. The highlights from the update included: SunMed Advisors, LLC has recently acquired majority control of CTYX through the purchase of Series A Preferred stock from the two principal holders of CTYX. Jon Pevzner, former President and Director has resigned, and Paul M. Michaels was appointed Interim CEO and Director. Dr. Barry A. Ginsberg and Brandon Michaels join Mr. Michaels on the Board. CTYX will continue to update shareholders on a new business plan through news releases, website updates and OTCMarkets filings as the company moves forward.

Innovation Pharmaceuticals Inc. (OTCQB: IPIX) has developed Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The company announced on March 9^th that. Brilacidin has been submitted for testing against SARS-CoV-2, the specific coronavirus responsible for COVID-19. Brilacidin is immediately being placed into queue and the Company anticipates confirmation of the testing schedule as well as procedures for the studies later this week.

Ever wish you were aware of a hot new sector before it experiences explosive growth? Hot new sector in its infancy gaining traction now READ MORE
Copy and paste to browser may be required – https://www.industrynews.tips/
Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRESS RELEASE PROCEDURES

The sponsored and non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To read our report(s), disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source